<DOC>
	<DOCNO>NCT02862145</DOCNO>
	<brief_summary>This study design investigate biomarkers , pharmacodynamics pharmacokinetics liposomal micro-ribonucleic acid-34 ( microRNA-34 , miR-34 ) . Melanoma patient easily accessible lesion undergo serial biopsy serial blood sample collect .</brief_summary>
	<brief_title>Pharmacodynamics Study MRX34 , MicroRNA Liposomal Injection Melanoma Patients With Biopsy Accessible Lesions</brief_title>
	<detailed_description>MRX34 Induction Therapy consist 3 cycle MRX34 treatment give approximately 8 week period . Dexamethasone 10 mg PO ( IV ) give premedication . On Days 1-5 treatment cycle , MRX34 give daily infusion follow 16 day rest . At screen tumor biopsy sample required patient . Additional biopsy collect Cycle 1 Day 3 end Cycles 1 3 ( Day 18 +/- 1 day )</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>≥18 year age Advanced metastatic cutaneous , acral mucosal melanoma Tumor lesion accessible serial biopsy ECOG ≤ 1 ANC ≥ , Plts ≥100,000 /mm3 Serious active nonmalignant disease Central Nervous System metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Biosy accessible melanoma</keyword>
</DOC>